The proposed research is directed at developing vaccines for prevention and therapy of lung cancer. Methods described to facilitate isolation and characterization of antigens that are immunogenic in human bronchial epithelial tumor cells. Emphasis is placed on antigens that are shared by independently derived bronchial tumors. Such molecules may be the basis for broadly effective vaccines for the prevention and therapy of lung cancer. The initial focus of these studies is an in vitro model in which multiple tumors are derived by carcinogens or oncogene transformation from the same anchorage dependent, contact inhibited, non-tumorigenic bronchial epithelial cell line. Availability of this panel of related normal and tumor cell lines facilitates the design of well-controlled experiments to identify shared tumor antigens.

Proposed Commercial Applications

The commercial application is to develop vaccines against lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA079372-01
Application #
2717559
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Program Officer
Duglas-Tabor, Yvonne
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Vaccinex, Inc.
Department
Type
DUNS #
City
Rochester
State
NY
Country
United States
Zip Code
14620